Thursday, March 12, 2026

 

08.30                 Registration Opens

​​

09.30 - 09.40   Welcome Addresses

Welcome Address by the conference president Michael von Bergwelt, Munich, Germany

​​

09.40 – 11.10   Plenary Session 1: Tumor immunology evolving

​Chair: Mascha Binder, Basel, Switzerland & Stefani Spranger, Cambridge, MA, United States

​

09.40 – 10.10            

01.01. How T cells see neoepitopes

Stefanie Spranger, Cambridge, MA, United States

​

10.10 – 10.40            

01.02. Metabolic control of T cells

Max Mazone, Leuven, Belgium

​

10.40 – 11.10            

01.03. CD27-CD70 axis in tumor immunology

Eric Tartour, Paris, France

​

11.10 – 11.40   Coffee Break

​

11.40 – 13.10   Plenary Session 2: Resistance mechanisms to immunooncological agents and how to break them

​Chair: Dieter Saur, Munich, Germany & Sonia Wörmann, Munich, Germany

​

11.40 – 12.10            

02.01. Transfer tumoral mitochondria to T cells as tumor evasion mechanism

Yosuke Togashi, Okayama, Japan

​

12.10 – 12.40

02.02. On Tregs and how they can be properly targeted

Sergio Quezada, London, United Kingdom

​

12.40 – 13.10

02.03. Rewiring immune suppression at local and distant sites

Maria Sibilia, Vienna, Austria

​​

13.10 – 13.40   Satellite Symposium 1

CLICK to view the detailed Programme

​​

13.40 – 13.50   Company Pitch 1

CLICK to view details

​

13.50 – 14.50   Lunch & Poster Viewing

​

14.50 – 15.00   Company Pitch 2

CLICK to view details

​​

15.00 – 17.00   Plenary Session 3: New targets and new leads

​Chair: José Saro Suarez, Geneva, Switzerland & Christoph Zielinski, Vienna, Austria

​

15.00 – 15.30            

03.01. New IO leads

Ana Anderson, Boston, MA, United States

 

15.30 – 16.00

03.02. Expect the unexpected modulating Nacl in cancer immunotherapy

Christina Zielinski, Jena, Germany

​

16.00 – 16.30

03.03. Current status of immunotherapy in breast cancer

Nadia Harbeck, Munich, Germany

​

16.30 – 16.45             

03.04. Anti-KIR2DL4 Stimulation Enhances the Cytotoxic Activity of NK-92 Cells Against Prostate Cancer

Mohammadreza Dastouri, Ankara, Turkey

 

16.45 – 17.00             

03.05. Aging drives immunosuppressive niches in gallbladder cancer: single-cell and spatial transcriptomic insights for immunotherapy

Lei Kong, Shanghai, China

​

17.00 – 18.00   Plenary Session 4: Anti-cancer vaccines

​Chair: Tanja de Gruijl, Amsterdam, Netherlands & Eric Tartour, Paris, France

​

17.00-17.30              

04.01. Dark genome-derived antigens as therapeutic targets

Bernie Fox, Portland, OR, United States

​

17.30-18.00              

04.02. Potential targets for combination therapy in melanoma

Patrizia Stoitzner, Innsbruck, Austria

 

18.00 – 20.00   Welcome Reception and Poster Viewing (at the venue)

​

​

Friday, March 13, 2026

​

08.00 – 09.00        Plenary Session 5: Advances in clinical immunotherapy of multiple myeloma – Part I

Chair: Djordje Atanackovic, Baltimore, MD, United States & tba

​​

08.00 – 08.30            

05.01. Predictors of response and resistance to immunotherapies against multiple myeloma

Maximilian Merz, New York, NY, United States

​​

08.30 – ​09.00            

05.02. Dynamic changes in myeloma tissue and its microenvironment as modulators and predictors of tumor immune responses

Julia Frede, Munich, Germany

​

09.00 – 09.30       Plenary Session 6: Moving grounds: IO reaching earlier lines of treatment – Part I

Chair: Chong Xian Pan, Boston, MA, United States & Alexander Eggermont, Utrecht, Netherlands

09.00 – ​09.30 

​06.01. Neoadjuvant immunotherapy in Bladder Cancer

Michiel S. van der Heijden, Amsterdam, Netherlands

​

09.30 – 10.30   Plenary Session 7: Technological advances in resolving tumor immunity

​Chair: Jürgen Ruland, Munich, Germany & Michael Bergmann, Vienna, Austria

​

09.30 – 10.00            

07.01. Modulating the microbiome for cancer immunotherapy

Bertrand Routy, Montreal, Canada

​​

10.00 – 10.30            

07.02. Spatial transcriptomics and secretomics analysis to unravel potential therapy resistance mechanisms in esophageal cancer

Sarah Derks, Amsterdam, Netherlands

​

10.30 – 11.00   Coffee Break

​

11.00 – 12.30        Plenary Session 8: Immune engagers

Chair: Michael Hölzel, Bonn, Germany & Pedro Romero, Lausanne, Switzerland

​

11.00 – 11.30            

08.01. Opportunities and Challenges of CD47 targeted therapy in cancer immunotherapy: Bispecific antibodies targeting CD47

Victor Moreno, Madrid, Spain

​

11.30 – 12.00            

08.02. DLL3-CD3 bispecific antibodies in Small cell lung cancer

Rosa Nadal Rios, Seattle, WA, United States

​​

12.00 – 12.30            

08.03. How to enhance bispecific antibody activity

Marion Subklewe, Munich, Germany

​

12.30 – 13.00        Satellite Symposium 2

CLICK to view the detailed Programme

​

13.00 – 13.30        Satellite Symposium 3

CLICK to view the detailed Programme

​

13.30 – 14.30   Lunch & Poster Viewing
 

14.30 – 15.15        Plenary Session 9: Lifetime Achievement Award presented to Prof. Dr. John Haanen

Chair: Sebastian Kobold, Munich, Germany & Michael von Bergwelt, Munich, Germany

​

09.01. Ways to engage endogenous T cell immunity to fight cancer

 John Haanen, Amsterdam, Netherlands

​​

15.15 – 16.30       Plenary Session 10: Moving grounds: IO reaching earlier lines of treatment – Part II

Chair: Chong Xian Pan, Boston, MA, United States & Alexander Eggermont, Utrecht, Netherlands

​

15.15 – 15.45            

10.01. Adjuvant IO is no more? Curing with neoadjuvant concepts: an overview

Alexander Eggermont, Utrecht, Netherlands

​​

15.45 - 16.15        Plenary Session 11: Advances in clinical immunotherapy of multiple myeloma – Part II

​Chair: Djordje Atanackovic, Baltimore, MD, United States & tba

​

15.45 – 16.15             

11.01. The evolving landscape of myeloma immunotherapy

Djordje Atanackovic, Baltimore, MD, United States

​

16.15 – 16.30             

11.02. β-adrenergic blockade unleashes cytotoxic CD4 T cell immunity in cancer

Daniel Hargbøl Madsen, Herlev, Denmark

​

16.30 – 17.00   Coffee Break

​

17.00 – 18.00        Plenary Session 12: Young Researcher Session (from submitted abstracts)

​Chair: Stefan Endres, Munich, Germany &​ Louisa von Baumgarten, Munich, Germany

​

17.00 – 17.15             

12.01. Increased teclistamab dosing interval improves clonotypic diversity and reduces infection risk in multiple myeloma

Nazia Afrin, Würzburg, Germany

 

17.15 – 17.30             

12.02. ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer

Charlotte Orschel, Cologne, Germany

 

17.30 – 17.45             

12.03. Menin inhibition following allo-HCT enhances graft-versus-leukemia effects through endogenous retrovirus induction in AML and T-cell activation

Viktor Fetsch, Freiburg, Germany

 

17.45 – 18.00             

12.04. A modular CAR T cell platform for targeted immunotherapy of acute myeloid leukemia

Anja Hauptstein, Munich, Germany

​​​

18.05 – 19.00   Poster Viewing with Presenters
 

19.30   ITOC12 Conference Dinner

​

​

Saturday, March 14, 2026

​​

09.00 – 10.30   Plenary Session 13: Immunooncology in gynecologic oncology

​Chair: Sven Mahner, Munich, Germany & Fabian Trillisch, Munich, Germany

​

09.00 – 09.30

13.01. New immunooncological approaches in endometrial cancer​

Fabian Trillsch, Munich, Germany

​​​​

09.30 - 10.00               

13.02. Immunotherapy of Ovarian Cancer

Frederik Marmé, Mannheim, Germany

​​

10.00 – 10.15             

13.03. Cancer cell–intrinsic rewiring of the secretome in immune-excluded colorectal cancer

Krijn Dijkstra, Utrecht, Netherlands

 

10.15 – 10.30

13.04. The combination of Innate immunity, activating tumor associated macrophages and adaptive immunity, a promising therapeutic approach in heavily treated platinum resistant ovarian cancer patients

Julien Montorfani, Plan-Les-Ouates, Switzerland

​​​

10.30 – 11.30       Plenary Session 14: Cellular therapies beyond T cells

​Chair: Philipp Beckhove, Regensburg, Germany & Reda Benmebarek, Heidelberg, Germany​

​

10.30 – 11.00            

14.01. IPSC as universal source of therapeutic cells

Maria Themeli, Amsterdam, Netherlands

​​

11.00 – 11.30            

14.02. Transient immune cell engineering: sufficient with innate help?

Andrea Ablasser, Lausanne, Switzerland

​

11.30 – 12.00   Coffee Break

​

12.00 – 13.30   Plenary Session 15: CAR- and TCR- engineered T cells

​Chair: Marion Subklewe, Munich, Germany & Johanna Olweus, Oslo, Norway​

​

12.00 – 12.30            

15.01. CRISPR engineering of T cells for cancer therapy

Franziska Bläschke, Heidelberg, Germany

                                  

12.30 – 13.00            

15.02. TCR T cells against novel targets

Johanna Olweus, Oslo, Norway

​

13.00 – 13.15             

15.03. Myeloid-T Cell Therapy Interactions Reshape the Tumor Microenvironment to sustain Tumor Control

Alfredo Pherez Farah, Padua, Italy

                                      

13.15 – 13.30             

15.04. Metabolic reprogramming enhances stem-like and functional properties of lung cancer-derived TILs

Abhishek Tomar, Galway, Ireland

​

13.30 – 13.45             

15.05. Development of peptide-centric CARs targeting IGFBPL-1 for cancer immunotherapy in small-cell lung cancer

Benjamin McEnroe, Bonn, Germany

​​

13.45 – 14.15   Plenary Session 16: Best Poster Awards & Closing Remarks

​Chair: Sebastian Kobold, Munich, Germany & Michael von Bergwelt, Munich, Germany

​

14.15 – 15.00   Lunch & Farewell

​

​